Bionano Genomics Inc BNGO.OQ BNGO.O is expected to show a fall in quarterly revenue when it reports results on August 14 for the period ending June 30 2025
The San Diego California-based company is expected to report a 12.1% decrease in revenue to $6.832 million from $7.77 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on May 14 2025, for the period ended June 30, was for revenue between $6.30 million and $6.80 million.
LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of $2.41 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bionano Genomics Inc is $8.00, about 63.4% above its last closing price of $2.93
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -3.32 | -3.02 | -1.15 | Beat | 61.9 |
Dec. 31 2025 | -6.00 | -15.83 | Missed | -163.8 | |
Sep. 30 2024 | -11.92 | -12.60 | -24.00 | Missed | -90.5 |
Jun. 30 2024 | -24.74 | -25.00 | -13.20 | Beat | 47.2 |
Mar. 31 2024 | -38.68 | -38.70 | -30.60 | Beat | 20.9 |
Dec. 31 2023 | -52.16 | -52.35 | -24.60 | Beat | 53 |
Sep. 30 2023 | -55.33 | -58.20 | -60.00 | Missed | -3.1 |
Jun. 30 2023 | -60.00 | -62.00 | -74.40 | Missed | -20 |
This summary was machine generated August 12 at 20:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)